Last edition
News about "CAR T-cell therapy "
Gilead Sciences and Kite Pharma to present new ASCO and EHA 2026 data highlighting progress in Antibody Drug Conjugates (ADCs) and CAR T-cell therapies, including updates on Trodelvy and anito-cel for difficult-to-treat cancers.
CAR T-cell Therapy | 22/05/2026 | By News Bureau
TDB-DST Backs Helix Cell Therapeutics for CAR-T Therapy against Multiple Myeloma
Technology Development Board (TDB) supports Helix Cell Therapeutics and Biocell Innovations in developing dual-targeting CAR-T cell therapy for multiple myeloma under an Indo-Singapore collaboration.
CAR-T Cell Therapy | 14/05/2026 | By News Bureau
Gilead Sciences Completes Arcellx Inc. Acquisition Ahead of Anito-cel Launch
Under the terms of the transaction, Gilead acquired Arcellx for USD 115 per share in cash, plus one non?transferable Contingent Value Right (CVR) of USD 5 per share, representing a total implied equity value of approximately USD 7.8 billion at the time of closing.
CAR T-cell Therapy | 29/04/2026 | By News Bureau
IASO Biotechnology Partners with Instituto Butantan to Localise CAR-T Therapy in Brazil
IASO Bio licenses CAR-T technology to Instituto Butantan for local development in Brazil, aiming to reduce treatment costs and expand public access to advanced therapies for haematological cancer patients.
CAR-T Cell Therapy | 13/04/2026 | By News Bureau | 113
Biocytogen Grants Licence for RenNano Platform to Taisho Pharmaceutical
Biocytogen licenses its RenNano platform to Taisho Pharmaceutical to advance fully human heavy chain-only antibody discovery, supporting in-vivo screening and downstream research.
CAR-T Cell Therapy | 31/03/2026 | By News Bureau
Oricell Therapeutics Raises USD 70M in Series C1 to Advance CAR-T Therapies for Solid Tumors
The funding will accelerate global expansion and clinical development of Oricell’s CAR-T pipeline, including its lead hepatocellular carcinoma programme Ori-C101.
CAR-T Cell Therapy | 13/01/2026 | By News Bureau | 246
Bristol Myers Squibb Acquires Orbital Therapeutics
The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.
CAR T-cell Therapy | 13/10/2025 | By Dineshwori | 247
Made Scientific, Hemogenyx Partner to Advance CAR-T Cell Therapy for AML
Made Scientific and Hemogenyx Pharmaceuticals have announced a technology transfer and manufacturing partnership to advance HG-CT-1, an autologous CAR-T cell therapy for acute myeloid leukaemia (AML).
CAR-T Cell Therapy | 09/09/2025 | By Mrinmoy Dey | 146
CARsgen Initiates Investigator-Initiated Trial for Allogeneic CD19/CD20 CAR-T Therapy
KJ-C2219 is developed based on CARsgen's THANK-u Plus platform and is designed for the treatment of hematologic malignancies and autoimmune diseases.
CAR T-cell Therapy | 02/01/2025 | By Aishwarya | 491
Biosyngen Gets FDA Approval for BRG01 for Phase II Clinical Trial
Biosyngen has announced that the US Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.
CAR-T Cell Therapy | 13/08/2024 | By Aishwarya | 479
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy